News: Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,658JPY
30 Oct 2014
Price Change (% chg)

¥30 (+0.64%)
Prev Close
¥4,628
Open
¥4,649
Day's High
¥4,685
Day's Low
¥4,636
Volume
2,228,000
Avg. Vol
2,225,548
52-wk High
¥5,170
52-wk Low
¥4,338

Search Stocks
Select another date:

Mon, Oct 27 2014

CORRECTED-Nikkei falls after U.S. and German data sour mood; Fed eyed

(Corrects percentage decline in index and actual level in paragraph 5) * Strong retail sales lifts Seven & i, Aeon * Takeda soars after punitive damages slashed in Actos case * Fujifilm extends gains, but fund manager says its core business uncertain By Ayai Tomisawa TOKYO, Oct 28 - Japanese stocks fell Tuesday morning after Canon Inc tumbled on weak earnings and soft global data offset upbeat domestic retail figures as investors waited cautiously for the outcome o

U.S. judge slashes $9 billion award vs Takeda, Lilly over diabetes drug

- A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug, although she rejected their request for a new trial.

U.S. judge slashes $9 billion award vs Takeda, Lilly over diabetes drug

- A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug, although she rejected their request for a new trial.

UPDATE 2-US judge slashes $9 bln award vs Takeda, Lilly over diabetes drug

Oct 27 - A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug, although she rejected their request for a new trial.

U.S. judge pares $9 bln award against Takeda, Eli Lilly over drug

NEW YORK, Oct 27 - A U.S. judge on Monday slashed a $9 billion punitive damage award against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug to $36.8 million, according to a court filing.

BUZZ-Orexigen Therapeutics Inc: Diet drug launched

** Drugmaker's shares up 20 pct at $4.88, biggest intra-day percentage jump in more than two years

Seattle Genetics and Takeda's cancer drug meets main trial goal

- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

UPDATE 1-Seattle Genetics and Takeda's cancer drug meets main trial goal

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

Seattle Genetics, Takeda's cancer drug meets main goal in trial

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

CORRECTED-UPDATE 1-Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk

(Corrects number of decisions in Actos lawsuits from three to six in final paragraph)

Select another date:

Press Releases

Search Stocks